Moderna’s Coronavirus Vaccine Shows Signs Of Success In Preliminary Study
Here’s some positive news to kick off your week. On Monday, Drugmaker Moderna Inc. released the first human results from trials of its coronavirus vaccine.
RELATED: Thousands Of People Want To Be Exposed To Covid-19 To Help Speed Up Vaccine Development
According to WSJ.com, Moderna said that its experimental coronavirus vaccine induced immune responses in some of the healthy volunteers who were vaccinated in a clinical study, and the shots were generally safe and well-tolerated. The study results provide a positive sign about its capabilities to protect folks against the novel coronavirus.
The data suggest the vaccine — which code name is mRNA-1273, “has a high probability to provide protection from Covid-19 disease in humans,” Moderna Chief Executive Stephane Bancel said on a conference call this Monday morning. However, it was made clear that these results are just preliminary and only for a portion of the study participants. Now, if it proves to work safely in subsequent testing, the company’s vaccine could be ready for emergency use as early as the fall.
The U.S. Food and Drug Administration recently gave the biotech permission to begin the second stage of testing, the news site reports. But, it was also noted that many vaccines fail to pass, even after showing positive signs in early testing.
Finding an effective coronavirus vaccine has been a challenge for the last couple of weeks. It’s become a global priority in ending the pandemic and the US government leaders have put forward a quick timeline to have one by the end of 2020. This usually takes several years to develop a successful vaccine.
Press Play Below For More:
RELATED: WHO Confirms 70 COVID-19 Vaccines Are In Development, With 3 In Trial